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Severe malaria is a life-threatening complication of an infection with the protozoan parasite
Plasmodium falciparum, which requires immediate treatment. Safety and efficacy concerns
with currently used drugs accentuate the need for new chemotherapeutic options against
severe malaria. Here we describe a medicinal chemistry program starting from amicarbalide
that led to two compounds with optimized pharmacological and antiparasitic properties.
SC81458 and the clinical development candidate, SC83288, are fast-acting compounds that
can cure a P. falciparum infection in a humanized NOD/SCID mouse model system. Detailed
preclinical pharmacokinetic and toxicological studies reveal no observable drawbacks.
Ultra-deep sequencing of resistant parasites identifies the sarco/endoplasmic reticulum
Ca2þ transporting PfATP6 as a putative determinant of resistance to SC81458 and SC83288.
Features, such as fast parasite killing, good safety margin, a potentially novel mode of action
and a distinct chemotype support the clinical development of SC83288, as an intravenous
application for the treatment of severe malaria.
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T
he decline in global malaria mortality rates by 48% over the
previous decade has raised hopes of radical malaria
control1. However, the burden of malaria is still high.
There were 213 million cases of malaria and 438,000 deaths in
2015 alone, with 3.2 billion people at risk1. Moreover, much of
the success gained against malaria has been owed to the excellent
therapeutic efficacy of artemisinin derivatives and their partner
drugs, which together as an artemisinin-based combination
therapy (ACT) have formed the backbone of malaria control
since 2005 (ref. 2). However, the clinical efficacy of ACT is under
attack. Plasmodium falciparum strains have emerged that display
a delayed and possibly reduced responsiveness to ACT3. Such
early stage ACT resistant parasites have recently spread from
their place of origin at the Thai/Cambodian border across all of
Southeast Asia and run the risk of spreading further into Asia
and beyond4. The consequences would be devastating since
alternatives to ACTs are not readily available.
The evolving lack of chemotherapeutic options against malaria
accentuates the need for new antimalarial drugs. Such novel drugs
should exploit novel molecular targets and have distinct chemical
structures to protect them from cross-resistance mechanisms.
Several candidates that meet these criteria are in the development
pipeline5–14. However, many more would be needed to
compensate for the high attrition rate expected during the
clinical trials and to build up a stock of reserve antimalarial drugs
that can quickly replace first-line drugs should they fail.
In addition to novel drugs for the treatment of uncomplicated
malaria, there is an equally urgent need for a new generation
of drugs for the treatment of severe malaria. Severe malaria is a
life-threatening condition that inevitably leads to the death if
not treated immediately. The leading symptoms of severe
malaria include impaired consciousness, vital organ dysfunction,
hyperparasitaemia and the inability to take oral medicine.
Severe malaria is currently treated with intravenous (i.v.) or
intramuscular artesunate for at least 24 h or, if parenteral
artesunate or artemether are not available, with i.v. quinine15.
However, in addition to the resistance problem outlined above,
there are concerns regarding the safety of both treatment regimens.
i.v. artesunate has recently been associated with delayed
haemolysis in 7–21% of the treated patients16,17 and quinine is
known to cause tinnitus and other audiovisual disorders18.
We have recently shown that amicarbalide exerts a potent
antiplasmodial activity in vitro, with a half-maximal inhibitory
concentration (IC50) of 10 nM (ref. 19). Amicarbalide is a
benzamidine derivative that was used in veterinary medicine as
an antiprotozoal drug against babesiosis, theileriosis and
anaplasmosis20,21. Slow parasite clearance rates, high relapse
frequencies, poor oral bioavailability, undesirable mutagenic and
toxic side effects, and manufacturing safety issues were the
reasons why this drug is no longer in use21,22. Here we describe a
medicinal chemistry program starting from amicarbalide that
identifies two agents with improved pharmacological and
antiplasmodial properties. The two compounds, SC81458 and
SC83288, are fast-acting trophocidal drugs that eliminate
P. falciparum blood stage parasites both in vitro and in a
humanized non-obese diabetic/severe combined immuno-
deficiency (NOD/SCID) gamma c (NSG) mouse model system.
Detailed preclinical pharmacokinetic (PK) and toxicological
studies support the clinical development of SC83288 towards an
i.v. application for the treatment of severe malaria. We further
link the Ca2þ pump PfATP6 to reduced susceptibility to
SC83288 and SC81458.
Results
Optimization of benzamidines as antiplasmodials. Benzamidines
are generally associated with poor oral bioavailability, which is
explained by the strong basic character of the amidine group and
the formation of a stable cation23,24. To improve oral
bioavailability several strategies have been employed, including
mimetic replacement of the amidine group. We initially followed
this approach, starting with the East side of amicarbalide, while
maintaining the West-side amidine group and the benzamidino-
ureido-phenyl scaffold (Fig. 1). All compounds were tested
in vitro for their activity against asexual blood stages of the
multi-drug-resistant P. falciparum strain Dd2 (ref. 25).
The removal of the East-side amidino group or its complete
substitution by an amine, amide or ester group abolished the
antiplasmodial activity (Supplementary Table 1). We therefore
explored a wider range of substituents including carbonyl-amino,
amino-sulfonyl and amino-carbonyl groups, but decided to focus
on 40-sulfonamides because of their overall higher antiplasmodial
activity and the ease to synthesize a large number of derivatives.
A total of 20 sulfonamide derivatives were synthesized and
analysed in a reiterative process. The best activity (IC50 of
10±3 nM, n¼ 3; mean±s.e. of the mean of n independent
determinations) was obtained for compound SC09064,
where a bulky 40-sulfonamidomethyl benzene para-sulfonamido
group was introduced (Fig. 1). The compound had improved
physicochemical and absorption, distribution, metabolism, excre-
tion (ADMET) properties compared with the parent molecule
amicarbalide, including better solubility in water (316 versus
100 mgml 1), improved metabolic stability in a human micro-
some assay (65% residual after 1 h of incubation), negative in
Ames test, and no adverse effects on HepG2 cells at a
concentration of 10 mM. However, the permeability as determined
in CACO 2 cells (Papp¼ 0.28 10 6 cm s 1) and the oral
bioavailability (3% in rats) remained poor, which we attributed to
the presence of the remaining amidine group on the West side of
the molecule.
The West-side amidine group of SC09064, however,
was essential for the antiplasmodial activity and replacing
it with amines or uretanic groups rendered the compound
inactive (Supplementary Table 1). We therefore explored a series
of modifications of the amidine group and found that
functionalizing it with a piperazine ring produced compounds
with high antiplasmodial activity (Fig. 2; Supplementary Table 1).
However, introducing the piperazine ring did not significantly
improve the permeability, falling short of the targeted value of
Papp410 10 6 cm s 1. The best two compounds in terms of
activity and permeability were SC81458 and SC83288 with IC50
values of 8±1 nM (n¼ 6) and 3±1 nM (n¼ 6), and Papp values
of 0.76 10 6 and 0.42 10 6 cm s 1, respectively (Table 1;
Fig. 3a; Supplementary Table 2). Additional criteria driving the
medicinal chemistry optimization were solubility in water
(Supplementary Table 2) and therapeutic efficacy in a rodent
malaria model system (see below). Synthesis scheme and
analytical chemistry of SC81458 and SC83288 are depicted in
Supplementary Figs 1 and 2. Figure 2 summarizes the structure-
activity relationship of all 172 derivatives evaluated during the
course of the hit to lead optimization campaign.
SC81458 and SC83288 are fast-acting antiplasmodial compounds.
Due to the steep dose–response curves, SC81458 and SC83288
have favourable IC90 (18 and 8 nM, respectively) and IC99 (50 and
20 nM, respectively) values in parasite growth assays (Fig. 3a;
Table 1). SC81458 and SC83288 were also active against a range
of drug-resistant P. falciparum lab strains other than Dd2, with
IC50 values consistently beingo20 nM (Supplementary Table 3).
These data suggest that SC81458 and SC83288 are able to
overcome established antimalarial drug resistance mechanisms.
Both compounds were also active against early stage (I–III)
gametocytes, with IC50 values of 76±6 nM (n¼ 3) and
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199±30 nM (n¼ 3), respectively; however, they showed
negligible activity against late stage (IV and V) gametocytes
(SC81458 IC50¼ 1.8±0.2 mM, n¼ 3; SC83288 IC50 430 mM).
The activities against liver and insect stages were not determined.
Because of their excellent in vitro activity against P. falciparum
asexual blood stages, together with the opportunity to develop a
needed alternative i.v. treatment for severe malaria, we further
evaluate SC81458 and SC83288 despite their lack of oral
bioavailability. We first investigated the stage-specific activity of
the two compounds. To this end, highly synchronized cultures
of Dd2-containing rings (2–4 h post invasion), trophozoites
(24–26 h post invasion) and schizonts (35–37 h post invasion)
were exposed to different concentrations of the compound for
6 h. Cells were subsequently washed and placed in drug-free
medium until time point 10 h post invasion of the following cycle,
when [3H] hypoxanthine was added for 24 h to determine cell
viability. Under these conditions, both SC81458 and SC83288
exerted the highest activity against trophozoites with IC50 values
of 37±3 and 40±4 nM, respectively (n¼ 4; Fig. 3b,c). A slightly
lower activity was observed against schizonts, with IC50 values of
70±10 and 110±30 nM, respectively (n¼ 4; Fig. 3a,c). The
activity against ring stages was only moderate, with IC50 values of
5±1 and 3±1 mM, respectively (n¼ 4; Fig. 3b,c). Note that IC50
values have to be interpreted in the context of the exposure
time—6h in the stage-specific assays versus 72 h in the standard
proliferation assays.
To assess how quickly the two compounds were able to kill the
parasite, we exposed highly synchronized trophozoites (24–30 h
post invasion; 0.5% parasitemia) of Dd2 to different drug
concentrations ranging from 0.1 to 10 mM (ref. 7). Aliquots
were withdrawn at different time points (from 0 to 6 h) after the
addition of the drug and analysed for cell viability by [3H]
hypoxanthine incorporation. Parasite clearance depended on
both drug concentration and exposure time (Fig. 4a). For
instance, SC83288 cleared a 0.5% parasitemia at a concentration
of 500 nM within an exposure time of 3±1 h (n¼ 4). Artemisinin
revealed a slower killing efficacy for trophozoites under these
conditions (Fig. 4a).
Since this assay underestimates parasite recrudescence, we
adopted a second, standardized protocol that assessed parasite
viability as a function of drug exposure time based on limiting
serial dilutions of treated parasites and re-growth monitoring26.
For comparative reasons, artemisinin and atovaquone were
analysed in parallel. Each drug was applied at a fixed
concentration of 10 times its IC50 value in Dd2, which were 80
and 30 nM for SC81458 and SC83288, respectively, and 19 and
10 nM for artemisinin and atovaquone, respectively. SC81458
and SC83288 cleared 99.9% of the initial parasite population
(parasite clearance time (PCT99.9%)) within 37±4 h and 51±6 h,
respectively, corresponding to a parasite reduction rate of
3.4±0.4 and 3.0±0.5 log phases over a period of 48 h (logPRR
(parasite reduction ratio); n¼ 4; Fig. 4b; Table 1). Both
compounds acted quickly with a lag time of o5 h. In
comparison, atovaquone is less potent as indicated by a
PCT99.9% of 89±7 h, a logPRR of 2.1±0.4 and a lag time of
424 h (n¼ 4). Artemisinin, however, displayed a higher activity
in this assay with a PCT99.9% of 21±3 h, a logPRR of 4.5±2 and a
zero lag time (n¼ 4)26.
Safety profile of SC81458 and SC83288. Profiling SC81458 and
SC83288 against a panel of standardized cellular, biochemical and
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Figure 1 | Structures and in vitro activities of hit and lead compounds. The names of the compounds, their half maximal inhibitory concentrations (IC50),
and their molecular masses are indicated.
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physiological assays revealed no obvious off-target activities.
The two compounds did not affect in vitro propagation of Balb C
3T3 cells, HepG2 cells, human T-cells, or human peripheral blood
macrophages or showed any other signs of cytotoxicity at a fixed
concentration of 50 mM. They (10 mM) did not interfere with any
of the 401 human kinases examined in a competition assay
(Supplementary Table 4). The binding potential to 54 human
transporters and receptors was low to moderate, with none
of the interactions occurring in the pharmacologically relevant
concentration range (Supplementary Table 5). SC81458 and
SC83288 did not block human cardiac hERG-mediated
Kþ conductance. hERG retained 490% of its activity at a
concentration of 60 and 20mM for SC81458 and SC83288,
respectively. At a concentration of 100 mM of SC83288 the
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Table 1 | Relevant activity parameters of SC81458 and SC83288.
SC81458 SC83288
IC50, IC90, IC99 (nM) 8, 18, 50 3, 8, 20
In vitro PCT99.9% (h) 37±4 (4) 51±6 (4)
In vitro logPRR 3.4±0.4 (4) 3.0±0.5 (4)
In vitro lag phase (h) o5 o5
In vivo PCT99.9% (h)* o48 48
In vivo logPRR* 5.3 (W2), 3.2 (3D7) 3.0
IC50/90/99, inhibitory concentration of 50, 90 or 99% of the maximal effect; PCT99.9%, clearance time of 99.9% of the original parasite population; PRR, parasite reduction ratio.
For the in vitro PCT99.9% and the in vitro logPRR the means±s.e. of the means of (n) independent determinations are shown.
*Obtained in the P. falciparum-infected humanized NSG mouse model system.
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Figure 3 | Susceptibility of the P. falciparum strain Dd2 to SC81458 and SC83288. (a) Growth inhibition by SC81458 (closed circles) and SC83288
(open circles) in a standard cell proliferation assay with an exposure time of 72 h. (b,c) Growth inhibition by SC81458 (b) and SC83288 (c) against rings
(R, closed circles), trophozoites (T, open circles) and schizonts (S, closed inverted triangles) after an exposure time of 6 h. The mean±s.e.m. are shown for
at least six independent replicates.
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channel remained 50% active. The inhibition potential of
SC81458 and SC83288 (10 mM) towards 13 human cytochrome
P450 enzymes was low and only the CYP2E1 isoform was
modestly inhibited by 30% by SC83288 (Supplementary Table 6).
SC81458 and SC83288 showed no signs of genotoxicity, at 50 mM,
in a reverse Ames test or of mutagenic or clastogenic activity in
an in vitro micronucleus assay at 60mM.
The maximal-tolerated i.v. bolus dose of SC83288 was
at 30mg kg 1 body weight (extrapolated initial drug plasma
concentration C0 of 65,600 ngml 1) and 15mg kg 1 body
weight (C0 of 27,300 ngml 1) in rats and mice, respectively.
Observed adverse effects included ataxia, respiratory symptoms
and sleepiness. However, all treated animals fully recovered
within 30min after drug application. Haematological and clinical
biochemical parameters assessed 24 h post application remained
within normal range in all animals (Supplementary Table 7).
Increasing the dose to 45mg kg 1 body weight caused apnoea in
rats. The no-observed-adverse-effect level and the no-observed-
effect level in rats corresponded to a tested i.v. bolus dose of
22.5mg kg 1 body weight (C0 of 49,200 ngml 1) and
15mg kg 1 body weight (C0 of 32,800 ngml 1), respectively.
Stability and in vitro metabolism. SC81458 and SC83288 were
soluble in water (890 and 940 mgml 1, respectively) and organic
solvents. Measured pK values were 5.72 and 9.78 for SC81458 and
9.82 for SC83288. The solubility in phosphate buffer decreased
with increasing pH, from 1.8mM at pH 4 to 0.4mM at pH 9 for
SC81458 and from 2.6mM at pH 4 to 0.8mM at pH 9 for
SC83288 (Supplementary Fig. 3). The compounds were stable in
different physiological solutions, including artificial gastric juice,
simulated intestinal fluid, phosphate-buffered saline and human
plasma, when incubated for 6 h at 37 C.
The in vitro elimination and metabolic profile of SC81458 and
SC83288 were determined using mouse, rat, dog, monkey and
human liver microsomal incubations with initial compound
concentrations of 10 mM. SC81458 was almost completely
metabolized by monkey and human liver microsomal extracts
during the 60min incubation time, with an apparent intrinsic
clearance of 303 ml min 1mg 1 (Supplementary Fig. 4a). The
compound was more stable in dog, mouse and rat microsomal
extracts, with 37%, 54% and 74% of the initial amount remaining
after 60min of incubation, respectively (Supplementary Fig. 4a).
In comparison, SC83288 was metabolically more stable.
The remaining abundances of SC83288 in mouse and rat
liver microsomal extracts were 96% and 91%, respectively
(Supplementary Fig. 4b). In dog, monkey and human liver
microsomal extracts, 83%, 51% and 50% of the compound
remained after the 60min incubation period, respectively
(Supplementary Fig. 4b). In human microsomal incubations,
SC83288 declined with an apparent intrinsic clearance
of 75.8±2.5 ml min 1mg 1 (n¼ 3). The disappearance of
SC81458 and SC83288 was mainly cofactor dependent and thus
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driven by metabolic activity in all species (Supplementary
Fig. 4a,b).
The metabolite profiles of SC81458 and SC83288 were similar
in all species, with minor differences in terms of the relative
distribution of metabolites and the overall number of metabolites
generated (Fig. 5; Supplementary Figs 5 and 6). The main
biotransformations were hydroxylations (or N-oxidations),
dehydrogenations, and N-dealkylations and more specifically,
the cleavage of the N-butyl piperazine chain and the cleavage of
the ‘East-side’ 4-sulfamoylphenyl methylene group. The resulting
two major metabolites were fully characterized for their
antiplasmodial activity in vitro. Metabolite 1 (M6 and M10 for
SC81458 and SC83288, respectively; see Supplementary Figs 5
and 6) showed an IC50 value of 65 nM and metabolite 2 (M7 and
M18 for SC81458 and SC83288, respectively) of 5.0 mM. Both
major metabolites did not reveal off-targets effects in the standard
assays described above.
SC81458 and SC83288 were stable in the presence of cultured
human red blood cells and in P. falciparum cultures for at least
6 h, as indicated by the absence of metabolites or break-down
products, suggesting that neither the human erythrocytes nor
the parasite metabolically alter the compound (Supplementary
Fig. 7).
SC81458 and SC83288 cure a P. falciparum infection in mice.
We next evaluated the efficacy of SC81458 and SC83288 in
humanized NSG mice infected with the wild-type P. falciparum
strain 3D7 or the multi-drug-resistant strain W2. At day 7 post
infection when all mice had developed a patent parasitemia,
mice were treated intraperitoneally (i.p.) with 0, 2.5, 5.0 and
10.0mg kg 1 body weight of SC81458 or SC83288 once per day
over the next 4 days. In all treatment groups, parasitemia dropped
rapidly without an apparent lag phase and fell below detectable
levels between day 8 and 10 post infection (with the exception of
3D7-infected mice treated with 2.5mg kg 1 per day of SC81458;
Fig. 6). Maximal kill rates were observed at 10.0mg kg 1 per day
i.p., with SC81458 and SC83288 reducing the parasite burden by
B97 and 93% within the first 24 h. Over a replicative cycle of
48 h, SC83288 reduced the parasitemia by 99.9% or three log
phases (in vivo logPRR of 3.0 and in vivo PCT99.9% of 48 h) with
no distinction in activity between the two parasite strains tested
(Table 1; Supplementary Fig. 8a). In comparison, SC81458 was
more effective against W2 than 3D7 and the in vivo logPRR
ranged from 5.3 to 3.2 for the two strains (Table 1). All mice were
surveyed for possible parasitemia for the next 3 weeks. However,
no recrudescence of the infection occurred, with the exception of
3D7-infected mice treated with 2.5mg kg 1 of SC81458. None of
the animals showed signs of discomfort or intolerability during
and after the treatment regimens.
The two SC compounds were also active in the Plasmodium
vinckei rodent malaria model system. SC83288 administered i.p.
at a dose of 20mg kg 1 once per day for four consecutive days
fully cured the infection (initial parasitemia of 1.0% at time of
first administration). All treated mice survived the initial infection
and there was no recrudescence. In the case of SC81458, a dosing
regimen of 30mg kg 1 per day for 4 days reduced the parasite
burden by 97% (89.9% and 3.3% parasitemia in untreated and
treated mice at day 5, respectively). However, the infection
persisted and all treated mice died of a recrudescent parasitemia
in the days following the last administration of the compound.
Contrasting with the efficacy against P. falciparum and
P. vinckei, SC81458 and SC83288 were inactive against the
rodent malaria parasite Plasmodium berghei. This was the case for
both an in vivo 4 day dosing regimen of 30mg kg 1 per day
and an ex vivo one-cycle growth inhibition assay. Similarly,
the parental compound SC09064 (Fig. 1) revealed no activity
against P. berghei and it was also inactive against P. vinckei
(see Supplementary Table 8 for results on all derivatives tested
in rodent malaria model systems). Differential therapeutic
efficacy in various rodent model systems is a well-established
phenomenon and is typically associated with charged
compounds, such as positively charged amidines and negatively
charged phosphoric acid or carboxylic acid containing drugs27–29.
The phenomenon is explained based on selective uptake of
charged compounds through parasite-induced channels, termed
new permeation pathways, in the host cell plasma membrane
and species-specific characteristics of the new permeation
pathways27,28. Consistent with these previous findings,
derivatives containing a free and hence protonated amidine
group, such as SC09064, were generally inactive in the rodent
malaria model systems, whereas compounds in which the
amidine was functionalized as a piperazine revealed therapeutic
efficacy against P. vinckei but not against P. berghei in vivo
(Supplementary Table 8).
PKs of SC81458 and SC83288. Figure 7a,b depict the PKs of
SC81458 and SC83288 after a single i.p. dose in mice. In the case
of SC83288, the same dosages as used in the efficacy study were
administered, namely 2.5, 5.0 and 10.0mg kg 1. For SC81458,
a dose of 20mg kg 1 was investigated. In all cases, the plasma
concentrations (Cmax) peaked within 30min or less after drug
application, suggesting a rapid entrance of the drug into the
systemic circulation. The plasma concentrations then rapidly
declined with an effective half time t1/2 of 52min for SC81458 and
29 to 55min for SC83288 (Table 2). The AUC0-inf (area under the
curve) were 4,342 and 2,019 ng h 1ml 1 for the highest doses of
SC81458 and SC83288 examined.
To better understand the PK/pharmacodynamic (PK/PD)
relationship of SC83288, we analysed the in vivo growth
inhibition data (taken from Fig. 6d, time point: 2 days after
commencement of treatment) as a function of the free plasma
concentration, the latter being calculated from the Cmax values by
correcting for 89% plasma protein binding of SC83288 in mice
(Supplementary Table 9). A sigmoidal half-maximal effective
dose (ED50) model was fitted to the resulting data points, yielding
estimates for the ED50 and ED90 of 45 and 80 nM, respectively
(Supplementary Fig. 8b). The free-minimal parasiticidal concen-
tration (MPC) at which parasite growth was completely inhibited
was 200 nM for SC83288, in good agreement with the in vitro
growth inhibition data (Supplementary Fig. 8a, see Fig. 2a for
comparison).
A detailed i.v. PK of SC83288 in four different species revealed
that therapeutic plasma exposures can be achieved after a bolus
i.v. application (2mg kg 1 body weight in mice, rats and
cynomolgus monkeys and 1.7mg kg 1 body weight in dogs;
Fig. 7c). For instance, in cynomolgus, SC83288 reached a C0 of
7,338 ngml 1, which corresponds to B17 times the free MPC.
The plasma protein binding of SC83288 was 82% in cynomolgus
(Supplementary Table 9). The plasma level declined with a t1/2
initial of 16min, a t1/2 terminal of 320min and an effective t1/2 of
62min. SC83288 was cleared from the blood of the non-human
primate with a rate of 470ml h 1 kg 1. None of the animals
showed any signs of intolerance during or after i.v. application
of SC83288 at the concentrations indicated above. The PK
properties of SC83288 were distinct from those of the
parental compound SC09064 and the close amicarbalide relative
imidocarb with regard to area under the curve, plasma half-life,
clearance and volume distribution (Supplementary Fig. 9).
On the basis of the PK data in the four animal species, we
predicted the total plasma clearance of SC83288 in humans by
allometric scaling, taking into account the maximal life potential
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of the respective species and by applying the empirical approach
of the rule of exponents30. This yielded a predicted human
plasma clearance of 14.7 l h 1 for SC83288 (Fig. 7d). We further
fit a minimal physiologically based PK (mPBPK) model to the
plasma data of the preclinical species to predict the human
PK profile and to simulate different infusion schemes31
(Supplementary Fig. 10). The mPBPK model yielded a total
body clearance of 15.2 l h 1 (13.1 l h 1 with plasma binding
correction). Both an i.v. bolus injection of 25mg or an infusion of
15mg h 1 can result in therapeutically relevant plasma
exposures, according to the model (Supplementary Fig. 10).
Resistance to SC81458 and SC83288. To gain insights into the
mode of action and the mechanism of resistance, we attempted
to select mutant lines. No resistant parasites emerged during
exposure of 108 asexual blood stages to 100 nM compound for
60 days. These data suggest that the frequency of spontaneous
resistance emergence is very low, possibly below the single-point
mutation rate of 10 9. However, exposing a starting number of
1010 asexual blood stages to gradually increasing drug con-
centrations (from 50 nM to 1,000 nM) selected for resistant
parasite lines during a period of B240 days (Fig. 8a,b). Eight
clonal parasite lines displaying different levels of resistance were
obtained by limiting dilution and subjected to ultra-deep
sequencing (Fig. 8a,b; Supplementary Table 10). All clones dis-
played cross resistance to both SC compounds, suggesting that
SC81458 and SC83288 share a common mode of action and/or
the parasites possess the same mechanism of resistance (Fig. 8c).
Resistance to the SC compounds did not decrease susceptibility to
licensed antimalarial drugs (Supplementary Table 11).
Of the polymorphisms and copy number variations detected
in the drug selected clones three correlated with decreased
susceptibility to SC81458 and SC83288 (Fig. 8d). These
polymorphisms were coding mutations in Pf3D7_1447900
encoding the multi-drug resistance transporter 2 (PfMDR2; four
out of eight clones with mutation), Pf3D7_0106300 encoding the
Ca2þ transporting PfATP6 (all clones had different gene
modifications, six clones had mutations and four clones had
duplications of the gene) and Pf3D7_1241800 encoding a putative
ATP-dependent RNA helicase DBP9 (six clones; Supplementary
Fig. 11).
ATP-dependent RNA helicases DBP9 are generally involved in
RNA metabolism, including ribozyme assembly, splicing and
translation initiation32. The non-synonymous mutation identified
occurred in a repetitive region, changing a glutamic acid to
aspartic acid at position 533 (Supplementary Fig. 11a).
PfMDR2 belongs to the ABC transporter superfamily and is
localized at the parasite’s plasma membrane and, possibly, the
digestive vacuolar membrane33,34. PfMDR2 confers heavy metal
resistance and it contributes to decreased susceptibility to
atovaquone, mefloquine and quinine but not chloroquine35,36.
PfMDR2 is dispensable during asexual replication36. The
non-synonymous mutation found in several SC81458 and
SC83288 selected clones results in the substitution of the
positively charged amino-acid lysine for the negatively charged
amino-acid glutamic acid at position 412 in transmembrane
domain 6 (Supplementary Fig. 11b). It is tempting to speculate
that the introduction of the negative charge allows PfMDR2 to act
on the positively charged SC compounds and expel them from
the cell.
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Figure 6 | In vivo efficacy of SC81458 and SC83288 in P. falciparum-infected humanized NSG mice. NSG mice engrafted with human erythrocytes
were infected with the P. falciparum strains 3D7 (a,c) or W2 (b,d). The compounds SC81458 (a,b) or SC83288 (c,d) were administered i.p. once per day
over 4 days starting on day 7 post infection. Parasitemia was assessed each day from day 2 post infection up to 12 days. The mean±s.e.m. of four mice in
each treatment group are shown.
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PfATP6 plays a crucial role in Ca2þ homoeostasis in
P. falciparum by acting as the sarco/endoplasmic reticulum
(ER) Ca2þ pump and by facilitating Ca2þ transport across the
parasite’s digestive vacuolar membrane. The polymorphisms
identified include alanine to threonine substitutions at positions
108 and 109 within transmembrane domain 2 for SC83288
selected clones and, for SC81458 selected clones, a substitution of
tyrosine for phenylalanine at position 972 within the large
cytoplasmic loop (Supplementary Fig. 11c). In addition to
point mutations, the PfATP6 locus and flanking regions on
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Figure 7 | Pharmacokinetic profiles of SC81458 and SC83288. (a,b) Mean plasma concentration of SC81458 (a) and SC83288 (b) over time following
i.p. administration of the indicated doses in mice. (c) Mean plasma concentration of SC83288 over time following i.v. administration of 2mg kg 1 in
monkeys (closed circles), mice (open circles), and rats (closed inverted triangles) and of 1.7mg kg 1 in dogs (open triangles). For comparative reasons, the
SC83288 AUC of the i.p. 10mg kg 1 treatment group in mice is indicated in grey. The dotted lines show the lower limit of quantification (LLoQ). The
mean±s.e.m. are shown for at least three animals. Data were examined using a non-compartment analysis (NCA) and relevant PK parameters are
compiled in Table 2. (d) Four species allometric scaling of the plasma clearance rate (CL) of SC83288, according to Ring et al.30. The CL values were
corrected for the maximum life potential (MLP). The function y¼ axb was fitted to the data points, yielding values for a of 9.47 and b of 1.17 (R2¼0.997).
Extrapolation of the fit provided estimates of the human blood clearance rate (red circle).
Table 2 | Pharmacokinetic parameters of SC81458 and SC83288.
Compound SC81458 SC83288
Application i.p. i.v.
Species Mouse Mouse Rat Dog Cynomolgus
Dose (mg kg 1) 20 2.5 5 10 2 2 1.7 2
AUC0-inf (ng hml
 1) 4,342 646 1,089 2,019 891 1,419 2,262 4,253
C0 (ngml
 1) 0 0 0 0 3,644 4,375 5,579 7,338
Cmax (ngml
 1) 7,384 610 1,338 1,711 2,560 3,283 4,564 6,569
tmax (min) 30 5 5 30 5 5 5 5
t1/2 initial (min) NC NC NC NC 9 9 12 16
t1/2 terminal (min) 860 100 73 46 43 625 90 320
t1/2 effective (min) 52 33 29 55 12 52 35 62
MRT0-t (h) 1.24 0.79 0.69 1.33 0.28 1.25 0.84 1.50
CL (ml h 1 kg 1) 4,607 3,870 4,590 4,953 2245 1,410 884 470
VC (ml kg
 1) NC NC NC NC 549 457 359 273
F (%) 62 58 49 45 100 100 100 100
AUC, area under the concentration-time curve; C0, initial drug plasma concentration; Cmax, observed maximum plasma concentration after administration; CL, total plasma clearance of drug after
administration; F, relative bioavailability compared to i.v.; MRT, mean residence time of the unchanged drug in the systemic circulation; NC, not calculated; tmax, time of Cmax; t1/2, time required for the
concentration to fall to 50% of its initial value; Vc, apparent volume of the central or plasma compartment.
Data were examined using a non-compartment analysis.
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chromosome 1 were duplicated in SC83288 selected clones
(Fig. 8d). The duplications were of different nature. One clone
had the complete chromosome 1 duplicated, two clones shared
the same domain duplicated, but all four clones duplicated a total
of six genes, including PfATP6 (Supplementary Fig. 11d).
To understand if any of the mutations identified in the three
candidate genes might exist already in the P. falciparum
population, we checked the 3,500 samples from the MalariaGen
consortium (https://www.malariagen.net/data/catalogue-genetic-
variation-p-falciparum-v4.0). However, none of the mutations
were found; all were de novo.
The presence of both point mutations and gene amplification is
striking and suggests a critical role of PfATP6 in SC83288
resistance and, possibly, the antiplasmodial mode of action.
If SC83288 and SC81458 target PfATP6 then inhibition of this
pump would incapacitate the ER of its function as a Ca2þ store
and the concentration of free Ca2þ would increase in the
parasite’s cytoplasm. To investigate this hypothesis, we loaded
P. falciparum-infected erythrocytes with the Ca2þ sensitive
fluorochrome Fluo-4 and recorded dynamic changes in cytoplas-
mic free Ca2þ in a live cell confocal set-up. However, treatment of
the cells with SC83288 (10 and 20mM) or SC81458 (10 and 20mM)
did not affect cytoplasmic free Ca2þ (Supplementary Fig. 12).
In comparison, cyclopiazonic acid (CPA; 10mM), an established
inhibitor of PfATP6 (ref. 37), induced a strong Ca2þ responses in
the parasite’s cytoplasm (Supplementary Fig. 12). These findings
suggest that PfATP6 plays a role in resistance to the SC
compounds, but it does not seem to be the molecular target.
Discussion
SC81458 and SC83288 fulfil several criteria of the target candidate
profile for a molecule against severe malaria38. Both compounds
1,800a
b
c
d
1,500
1,200
900
SC
81
45
8 
IC
50
 
(nM
)
SC
81
45
8 
IC
50
 
(nM
)
SC
83
28
8 
IC
50
 
(nM
)
SC83288 IC50 (nM)
SC83288 selected
SC83288 SC81758
1237 1237 1237 1237
1599 1599
322 322
3x 3x 3x2x
322
325
2915 2915 2915
1599
1608
1599
1608
1599
1608
1599
1608
Replicative cycles
SC83458 selected
600
300
2,500
2,000
1,500
1,000
500
0
0 20 40 60 80 100
Replicative cycles
0
0
Clone 1
Clone 9
PF3D7_0716000
PF3D7_1112700
PF3D7_1317200
PF3D7_0212100
PF3D7_1038400
PF3D7_0529800
PF3D7_1106800
PF3D7_1245200
PF3D7_1465700
PF3D7_0929300
PF3D7_0719900
PF3D7_1466900
PF3D7_1401000
PF3D7_1474600
PF3D7_1221000
PF3D7_1308400
PF3D7_0515600
Clo
ne
 4
Clo
ne
 15
Clo
ne
 21
Clo
ne
 18
Clo
ne
 13
Clo
ne
 1
Clo
ne
 9
Clo
ne
 1i
PF3D7_1447900
(PfMDR2)
PF3D7_1241800
(RNA-helicase)
PF3D7_0106300
(PfATP6)
PFATP6 locus
amplification
Clone 1i
Clones 13/18
Clones 15/21Clone 4
20 40 60 80 100 120
104
103
102
101
100
104103102101100
Figure 8 | In vitro generation of SC81458 and SC83288-resistant P. falciparum clones. (a,b) B1010 infected erythrocytes were treated with
increasing concentration of SC81458 (a) or SC83288 (b) and the decrease in drug susceptibility was monitored over time. Clones obtained at different
time points during selection are indicated. The means±s.e.m. of at least three independent determinations are shown. (c) Cross resistance between
SC81458- and SC83288-selected clones. (d) Identified single-nucleotide polymorphisms (SNPs) and gene amplifications in the genome of resistant clones.
The arrows point in the direction of increased selective pressure. SNPs and gene amplifications associated with resistance to SC compounds are highlighted
in blue. This includes PfMDR2 (position 1237), a putative ATP-dependent RNA helicase DBP9 (position 533) and PfATP6 (position 322 and 325), as well as
an amplification of the PfATP6 locus.
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have advantageous parasitological properties. They display steep,
in vitro grow inhibition curves with IC50 valueso10 nM and IC99
values r50 nM (Table 1) and absolute Hill coefficients larger
than unity (2.6±0.3 for both compounds, Fig. 2a). We interpret
this concentration–response behaviour as evidence of a biological
threshold phenomenon. SC81458 and SC83288 act quickly,
killing Z99.9% of the parasites within the first 48 h of
treatment as demonstrated in a standardized in vitro assay26,38
and in the humanized NSG mouse model system (Figs 4 and 6).
The parasite reduction rate of three log units is a conservative
estimate given that, in human patients, parasite killing is aided by
the host’s immune system and splenic entrapment and clearance
mechanisms26. A logPRR of Z3.0 is considered a favourable
property of an antimalarial drug candidate38, although the value
is lower than that of artemisinin26. While the compounds are
primarily active against replicative blood stages, with trophozoites
being the most susceptible stage, they also target early stage
(I–III) gametocytes. Being devoid of activity against the late
stage gametocytes (IV and V) the compounds may not exert
appreciable transmission blocking activity. In vitro preclinical
profiling discovered no obvious liabilities. Moreover, all animals
tolerated exposure to the compounds at therapeutic concen-
trations without any signs of distress or discomfort. However, a
full evaluation of the safety of the compounds awaits further
toxicological studies, in particular acute and 28 day repeat-dose
toxicology in a non-rodent species.
Both SC81458 and SC83288 belong to a chemotype that has
not yet been used in malaria chemotherapy and that does not
reveal cross resistance to currently used antimalarials.
The analysis of SC83288- and SC81458-resistant clones
provided first clues about the possible resistance mechanisms
and/or the mode of action. Among the three candidate genes
associated with resistance Pf3D7_0106300 encoding the Ca2þ -
transporting PfATP6 stands out. The finding of both point
mutations and gene duplications suggests that Pf3D7_0106300 is
under strong selective pressure by the SC compounds. PfATP6 is
the sarco/ER Ca2þ pump of the parasite, and as such plays a vital
role in Ca2þ homoeostasis. PfATP6 was once considered a
putative target of artemisinin39,40. However, more recent studies
failed to validate this hypothesis41 and, instead, point towards a
mode of action of artemisinin that involves inhibition of a
phosphatidylinositol-3-kinase42.
SC81458 and SC83288 do not seem to target PfATP6. At least
no Ca2þ responses were induced in the parasite’s cytoplasm on
the addition of the SC compounds, as would have been expected
if SC81458 and SC83288 were to directly inhibit PfATP6. This
suggests a putative role of PfATP6 in the drug resistance
mechanism, possibly by acting as a compensatory mechanism for
the yet to be identified molecular target of the SC compounds.
Alternatively, mutated and amplified PfATP6 might affect the
intracellular distribution of the compounds by transporting the
compounds into a compartment, where the compounds are less
harmful to the parasite.
A comparable role in resistance can be envisaged for PfMDR2,
which when mutated might expel the SC compounds from
the cell. A function of PfMDR2 as an export system is
consistent with the subcellular localization of PfMDR2 at the
parasite’s plasma membrane33,34 and the fact that PfMDR2
confers heavy metal tolerance and contributes to decreased
susceptibility to several antimalarial drugs including quinine and
atovaquone35,36.
The role of the putative ATP-dependent RNA helicase DBP9 in
the mode of action/mechanism of resistance of the SC
compounds is less clear (Fig. 8). RNA helicases have not yet
been considered drug targets in malaria research, although
specific inhibitors have been developed in other systems43.
Although both SC compounds are able to cure a P. falciparum
infection in humanized NSG mice, SC83288 showed improved
metabolic stability, better efficacy over a wider dose range and less
strain variability, compared with SC81458 (Fig. 6; Table 1)—
therefore nominating SC83288 as a potential preclinical
development candidate. The dose finding experiments conducted
in the mouse challenge model, together with the resulting PK/PD
relationship, provide first estimates of dose projections of
SC83288 in humans. Taking into consideration that the initial
treatment against severe malaria is i.v. applied until the patient is
able to take oral medication for final parasite elimination, the
mouse PK/PD data suggest that a steady-state free plasma
concentration of 1.5 the free MPC of 200 nM maintained over
a period of o8 h suffices to reduce the initial parasite burden by
99.9% within 48 h (Supplementary Fig. 8a). Assuming a
parasitemia of 10% that is not uncommon in patients with severe
malaria, the total parasite burden will fall from its initial value of
B1012 infected erythrocytes (assuming a total red blood cell
count of 2–3 1013) to B109 or below if the additional
contribution of splenic clearance and immune killing mechan-
isms are considered. The parasite burden may even fall faster with
longer exposure times, as suggested by the in vitro killing speed
experiments revealing concentration and exposure-dependent
parasite killing kinetics (Fig. 4b). A free plasma concentration of
1.5 the free MPC of 200 nM translates to a total plasma
concentration of 860 ngml 1 (assuming 78% plasma protein
binding, Supplementary Table 9). Maintaining such a plasma
concentration would require infusion rates between 8.8 and
13.1mg h 1 given a total plasma clearance rate between
1,0250ml h 1 (lower estimate) and 15,180ml h 1 (higher
estimate; Fig. 7d). How long such an infusion should be
administered or whether i.v. or intramuscular bolus applications
suffice would await efficacy studies in clinical settings. The
projected dosing regimen would maintain a safety margin of
B55-fold assuming comparable i.v. no-observed-adverse-effect
level in rats and humans with a C0 of 49,200 ngml 1. In
summary, SC83288 may not match the favourable pharmaco-
logical and PDs properties of artemisinin in all aspects. However,
the attributes of SC83288 have to be considered in light of
the emerging resistance against artemisinin derivatives3,4 and the
adverse side effects observed in a substantial number of patients
treated with parenteral artesunate16,17. The role of SC83288 as an
alternative chemotherapeutic option will require extensive clinical
studies. However, the available preclinical data suggest that
SC83288 holds promise for an efficacious and safe clinical
candidate for the acute treatment of severe malaria.
Methods
Ethical clearance. All animal studies were carried out in strict accordance with
national and European guides for the care and use of laboratory animals (European
regulations; 2010/63/EU). The challenge studies using humanized NSG mice
were approved by the Centre d’Expe´rimentation Fonctionnelle (CEF, La
Pitie´-Salpeˆtrie`re, Paris) and the Ministe`re de l´Education Nationale,
de l´Enseignement Supe´rieur et de la Recherche (authorization number 01737.03).
All procedures pertaining to the PK studies were in compliance with the German
Animal Welfare Act and German regulations (TierSchG/TierSchVersV) and were
approved by the Regierung von Oberbayern, Mu¨nchen, (authorization number
55.2-1-54-2532.2-9-11; studies in mice and rats) and the Niedersa¨chsisches
Landesamt fu¨r Verbraucherschutz und Lebensmittelsicherheit,
Oldenburg (authorization numbers: 33.2-42502-05-LG-01-86/2012 and
33.2-42502-05-LG-01/2014/04 SA; studies in cynomolgus monkeys and dogs).
Chemicals. The following chemicals were purchased from the following vendors:
Sigma-Aldrich: sodium/potassium ATPase inhibitor ouabain, artemisinin,
atovaquone, 4-(chlorosulphonyl)phenyl isocyanate, 4-nitro-sulphonyl-4-aniline
and acetonitrile. Fisher Scientific: isopropanol, dimethylacetamide,
dichloromethane, dimethylformamide, diisopropylethylamine, 3-nitrobenzamidine,
3-aminobenzamidine; tin(II) dichloride dihydrate, formic acid, acetonitrile,
4-trifluoromethylaniline, 3-chloroaniline, 2-bromoaniline, 2-aminobenzonitrile,
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2-bromo-4,6-difluoroaniline, 3-tri-fluoromethyl-4-chloraniline,
3-trifluoromethylaniline, 2-bromo-4-trifluoromethylaniline, 3,6-bis-trifluoro-
methylaniline, 2,4-di-bromoaniline, butylamine, benzyl-amine, adamantylamine,
oxalamide and sulphamide. Acros Organics: 4-aminosulfonamide,
3-isocyanatobenzonitrile, n-butylpiperazine, 4-hydroxypiperidine, piperazine,
silica gel, 4-(4-bromophenylsulfonyl)aniline, 4-(4-nitrophenylsulfonyl)aniline,
4-(4-chlorophenylsulfonyl)aniline and methyl sulfoxide-d6. Maybridge Chemical
Comp. Ltd.: 1,1-dioxo-1H-benzothiophen-6-ylamine, 4-benzene-sulphonylpheny-
lamine and 3H-benzimidazol-5-ylamine. Molecular Probes: Fluo-4-AM,
Pluronic F-127 and Probenecid. The sarco/ER calcium ATPase inhibitor CPA
was purchased from Calbiochem.
Synthetic scheme for SC81458 and SC83288. SC81458 and SC83288 were part
of a focus library consisting of 172 compounds. Compounds were synthesized in
groups of 6 to 12 in small-scale laboratory preparations. Each compound was
purified by liquid chromatography, in most cases by preparative high-performance
liquid chromatography/mass spectrometry (HPLC/MS). Before being screened
in vitro each compound identity was confirmed by analytical HPLC/MS. If the
compound was active against P. falciparum blood stages compound identity was
confirmed by 1H nuclear magnetic resonance (NMR; Supplementary Note 1). In
addition, an 13C-NMR spectrum was collected for a number of key compounds,
including the hit compound SC09064 and the two lead compounds SC81458
and SC83288 (see below and Supplementary Note 1). Analytical HPLC–MS
determinations were performed with Waters 2,700 Autosampler, Waters 1,525
Multisolvent Delivery System and Micromass ZQ single quadrupole mass
spectrometer with electrospray source. Column: Chromolith Fast Gradient C18
(Merck), 50 2mm, with stainless steel 2 mm prefilter. Eluent A, H2Oþ 0.1%
HCOOH; eluent B, MeCN. Preparative HPLC–MS were performed with a Waters
2,700 Autosampler, Waters 600 Multisolvent Delivery System with preparative
pump heads (500 ml), Waters 600S Controller and Waters ZQ single quadrupole
mass spectrometer with electrospray source. Column: Waters X-Terra RP18, 5 mm,
19 150mm. Eluent A, H2Oþ 0.1% HCOOH; eluent B, MeCN. Different linear
gradients, individually adapted to sample. Bioanalytical HPLC–MS for PK analysis
were performed with Agilent 1100 HTLC System, HTS-Pal Autosampler and
Micromass Ultima triple quadrupole, mass spectrometer with electrospray source.
Column: Chromolith RP18, 50 4.6mm. Eluent A, H2Oþ 0.1% HCOOH; eluent
B, MeCN. 1H-NMR and 13C-NMR were performed with a Bruker AV300
(300.13Mhz) at a temperature of 305K. The compounds described in this
document were prepared according to methods described in the following synthesis
method. Steps (i and ii): production of the cyanourea compound (4). An amount of
28mmol of 3-aminobenzonitrile (1) were dissolved in 40ml dichloromethane
(DCM). An amount of 27mmol of 4-isocyanatobenzene-1-sulfonyl chloride (2)
were added portionwise over 20min and the mixture was allowed to stir at room
temperature (RT) overnight. The urea product (3) precipitated, was filtered,
washed with cold DCM and was used directly in the next step (yield 93%). One
equivalent of 4-(aminomethyl)benzene-1-sulfonamide hydrochloride was dissolved
in MeCN and 1.5 equivalent N,N-diisopropylethylamine (DIEA) was added. The
solution was cooled to 0 C and, under vigorous stirring, 1 equivalent of the ureido-
sulfonylchloride compound was added portionwise. The reaction was allowed to
stir overnight, allowing the temperature to increase to RT. The solvent was eva-
porated and the product (4) was obtained by precipitation with ethylacetate/petrol
ether or MeOH/diethylether. If necessary, the product was further purified by flash
chromatography using a gradient of MeOH in DCM mixtures as eluent. [MþH]þ
calculated for C21H19N5O5S2, 486.090; found for [MþH]þ : 486.1. 1H-NMR
(300MHz, DMSO-d6) d¼ 3.97 (d, J¼ 6.2Hz, 2H), 7.22 (bs, 2H), 7.36–7.47 (m,
3H), 7.57–7.69 (m, 7H), 7.91 (t, J¼ 1.7Hz, 1H), 8.01 (t, J¼ 6.3Hz, 1H), 9.06 (s,
1H), 9.19 (s, 1H). 13C-NMR (75MHz, DMSO-d6) d¼ 45.54, 111.64, 118.00 (2 ),
118.74, 121.09, 123.17, 125.56 (2 ), 125.71, 127.81 (4 ), 130.20, 133.23, 140.19,
141.98, 142.91, 143.08, 152.16. Steps (iii and iv): conversion of the cyano com-
pound to functionalized benzamidine. Under argon atmosphere, 1 equivalent of the
cyanoureido (4) compound was dissolved with dry MeOH. An amount of 4M HCl
in dioxane was added and the solution was stirred overnight at RT. The solvent was
removed; the residue was taken in diethylether which was evaporated. This
operation was repeated three times to yield either a solid or an oily product. A
measure of 1 equivalent of the dried benzimidate was dissolved in N,N-dime-
thylformamide (DMF) and variable amounts of the chosen secondary amine were
added (1.0–1.1 equivalents). The solution was stirred overnight at temperatures
ranging from 55 to 70 C. The solvent was removed and the product was purified
by preparative HPLC and a gradient of acetonitrile in 0.1% HCOOH aq.
SC81458 (4-(3-(3-((4-butylpiperazin-1-yl)(imino)methyl)phenyl)ureido)-N-
(4-sulfamoylbenzyl) benzenesulfonamide) was prepared from 4-(3-(3-cyanophenyl)
ureido)-N-(4-sulfamoylbenzyl) benzenesulfonamide using 1.1 equivalents of
n-butylpiperazine as secondary amine. The product was purified by preparative
HPLC. Yield: 21%; [MþH]þ calculated for C29H37N7O5S2, 628.237; found for
[MþH]þ : 628.1; 1H-NMR (300MHz, DMSO-d6) d¼ 0.88 (t, J¼ 7.2Hz, 3H),
1.24–1.33 (m, 2H), 1.35–1.46 (m, 2H), 2.32–2.36 (m, 2H), 2.50 (m, 4H under
DMSO peak), 3.52–3.60 (bm, 4H), 4.03 (bs, 2H), 7.13 (d, J¼ 7.6Hz, 1H), 7.27–7.36
(m, 2H), 7.44 (d, J¼ 8.3Hz, 2H), 7.50 (t, J¼ 7.9Hz, 1H), 7.69–7.76 (m, 8H),
7.83–7.86 (m, 1H), 7.99–8.12 (m, 1H), 8.53 (s, 1H), 11.19–11.29 (m, 2H).
13C-NMR (75MHz, DMSO-d6) d¼ 13.81, 19.95, 28.23, 45.56 (3 ), 51.76 (2 ),
56.78, 116.99, 117.57 (2 ), 120.75, 121.18, 125.55 (2 ), 127.66 (2 ), 127.81
(2 ), 129.64, 129.85, 132.42, 141.09, 142.02, 142.91, 144.17, 152.94, 163.94, 167.24
(HCOO ). element. anal.: element: (calc. comp. incl. add. (%)/found (%)):
C: (53.56/51.82), H: (5.69/5.9), N: (14.57/14.16), S: (9.53/9.2). Oxygen not
determined.
SC83288 (methyl 4-(imino(3-(3-(4-(N-(4-sulfamoylbenzyl)sulfamoyl)phenyl)
ureido) phenyl)methyl) piperazine-1-carboxylate) was prepared from 4-(3-
(3-cyanophenyl)ureido)-N-(4-sulfamoylbenzyl)benzenesulfonamide using 1
equivalent of methyl piperazine-1-carboxylate as secondary amine. The product
was purified by preparative HPLC. Yield: 13%; [MþH]þ calculated for
C27H31N7O7S2, 630.180 ; found for [MþH]þ : 630.1; 1H-NMR (300MHz,
DMSO-d6) d¼ 3.28–3.32 (m, 2 H), 3.55–3.62 (m, 6H), 3.64 (s, 3H), 4.03
(d, J¼ 6.1Hz, 2H), 7.21 (d, J¼ 7.5Hz, 1H), 7.29 (bs, 2H), 7.44 (d, J¼ 8.3Hz, 2H),
7.54 (t, J¼ 7.9Hz, 1H), 7.63–7.78 (m, 7H), 7.86–7.89 (m, 1H), 8.08 (t, J¼ 6.3Hz,
1H), 9.39 (bs, 1H), 9.90 (s, 1H), 9.96 (s, 1H). 13C-NMR (75MHz, DMSO-d6)
d¼ 42.23 (2 ), 45.55 (3 ), 52.58, 117.43, 117.74 (2 ), 121.46, 121.60, 125.56
(2 ), 127.80 (4 ), 129.63, 129.81, 132.97, 140.37, 142.01, 142.91, 143.47, 152.41,
154.92, 164.39. element. anal.: element: (calc. comp. incl. add. (%)/found (%)):
C: (48.68/48.25), Cl: (5.32/4.77), H: (4.84/5.6), N: (14.72/14.51), O: (16.81/18.1),
S: (9.63/7.99).
Permeability assay. The study was conducted by Cyprotex (Macclesfield, United
Kingdom). CACO 2 cells (Sigma-Aldrich, catalogue: 86010202) were seeded on
Millipore Millicell plates and formed a confluent monolayer over 20 days before the
experiment. On day 20, the tested compounds at a final concentration of 10 mM
were added to the apical side of the membrane. The transport of the compound
across the monolayer was monitored over a 2 h period by liquid chromatography
(LC)–MS/MS quantification. The permeability coefficient (Papp) was calculated
from the following equation: Papp ¼ dQ=dtC0A , where dQ/dt is the rate of permeation of
the drug across the cells, C0 the donor compartment concentration at time zero and
A the area of the cell monolayer. C0 was obtained from analysis of the dosing
solution at the start of the experiment.
Cell culture. P. falciparum parasites were maintained in continuous in vitro
culture as previously described44. Briefly, blood cultures were grown in 10ml petri
dishes at 37 C under controlled atmospheric conditions of 3% CO2, 5% O2, 92%
N2 and at a humidity of 95%. Cells were grown at a haematocrit of 5.0% and at a
parasitemia of no 45%.
IC50 measurement. Growth inhibition assays were performed according to
standard protocols based on the detection of parasitic DNA by fluorescent SYBR
green staining45 or by [3H] hypoxanthine incorporation25. Briefly, a previously
sorbitol-synchronized culture of P. falciparum Dd2 ring-stage parasites was
incubated in the presence of decreasing drug concentrations in a 96-well black
microtiter plate, at the following final conditions: 100ml per well, 0.5% parasitemia,
2% haematocrit, incubation at 37 C. If parasite proliferation was assayed using
SYBR green, plates were incubated for 72 h, before being frozen at  80 C
overnight. On the day of the measurement, plates were thawed for 1 h at RT. An
amount of 100 ml a 1 SYBRGreen (ThermoFisher Scientific Inc.) solution in lysis
buffer was added to each well. The plates were then briefly shaken and incubated at
RT for 1 h in the dark. Fluorescence was measured in a fluorescence plate reader
(FluoStar Optima, BMG Labtech GmbH; ext/em: 485/520 nm, gain 1,380, 10
flashes per well, top optic). If parasite proliferation was assayed using [3H]
hypoxanthine incorporation, 0.5 mCi [3H]-hypoxanthine was added to each well
over the last 24 of the 72 h incubation period. Cells were collected on glass-filter
plates, which was dried at 60 C for 1 h. An amount of 20ml of scintillation cocktail
was added and the incorporated radioactivity was determined using a microtiter
plate scintillation counter. The IC50 values were calculated using SigmaPlot 13
(Systat Software Inc.) according to the Hill function (four parameters).
In vitro speed of action. The in vitro speed of action of SC81458, SC83288,
artemisinin and atovaquone on Dd2 P. falciparum parasites was assessed according
to two different protocols: first, we adapted the previously established protocol by
Sanz et al.26 and performed the assay using standardized conditions. Briefly,
asynchronous cultures (0.5% parasitemia and 2% haematocrit) with a predominant
ring population were treated with the selected drugs at concentrations
corresponding to 10 times their respective IC50 values. Drugs were renewed daily
over the entire treatment period. Samples of untreated (0 h) and treated parasites
(8, 24, 48, 72, 96, 120, 144 and 168 h) were aliquoted to perform serial dilutions
(dilution factor of 3, 12 dilution points) in 96-well plates in triplicates by adding
fresh erythrocytes and fresh culture medium. Before the serial dilution the drugs
were washed out using fresh culture medium. Parasites were cultured for 21 days to
allow wells with viable parasites to render detectable parasitemia, observed by
SYBRGreen staining as described above. The number of viable parasites in the
original aliquot was back calculated by using the formula Xn 1, where n is the
number of wells able to render growth and X is the dilution factor. The logarithm
of viable parasites þ 1 was plotted against time and fitted to a four parameter
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logistic curve using SigmaPlot 13 (Systat Software Inc.). From there, the lag phase,
the logPRR, and the PCT99.9% were determined for each drug.
The second approach followed the protocol described by Vial et al.7. Briefly,
highly synchronized trophozoite-stage parasites (24–26 h post invasion; 0.5%
parasitemia, 2% haemtocrit) were treated with 100, 500, 1, 5 and 10 mM of
artemisinin, SC81458 and SC83288 for up to 6 h (0 h, 10min, 30min, 1 h, 2 h, 3 h,
4 h, 5 h and 6 h), before the drugs were washed out and cells returned to culture. At
time point 10 h post invasion of the following cycle, [3H]-hypoxanthine was added
for 24 h to monitor parasite viability46. The clearance time was determined for each
treatment condition and was expressed as a function of the drug concentration.
In vitro metabolism in liver microsomes. The study was conducted by Novamass
Ltd (Oulu, Finland). The in vitro disappearance and metabolite profile of SC81458
and SC83288 was determined using mouse, rat, dog, monkey and human liver
microsomal incubations with initial substrate concentrations of 10 mM. Briefly,
SC81458 and SC83288 were incubated with liver microsomes (0.5mg of
microsomal protein per millilitre) in the presence of the appropriate cofactor.
Two parallel incubates, one with cofactor and one without, were employed. Each
reaction mixture was preincubated for 2min at 37 C. Reaction was started by
addition of 1mM NADPH and 1mM UDPGA. After incubation period of 0 or
60min, samples were collected and the reaction was terminated by addition of
ice-cold acetonitrile. Samples were subsequently cooled in an ice bath and
centrifuged (10min, 16,100g). The supernatants were transferred to maximum
recovery vials and analysed by LC/MSMS.
Determination of efficacy in the Pf/NSG mouse model. NSG male mice aged
9–11 weeks (Charles River, US) were used for this study. They were kept in sterile
isolators, provided with UV light-exposed commercial food and autoclaved water
ad libitum. Human red blood cells (HRBC) were obtained from the Etablissement
Franc¸ais du Sang (Ile-de-France, Rungis). HRBC were washed twice with
RPMI-1640 medium (Gibco/BRL) by centrifugation at 900g, 10min at 25 C
resuspended in RPMI-1640 medium and kept at 4 C for a maximum of 2 weeks.
Mice humanization and P. falciparum infection was carried out as previously
described47. Mouse tissue macrophages were depleted by clodronate, provided by
Roche Diagnostics (Mannheim,Germany), encapsulated in liposomes (lip-clod) as
previously described48. Neutrophils were controlled using the monoclonal antibody
(mAb) NIMP-R14 (the monoclonal antibody NIMP-R14 was purified from a
hybridoma provided by Dr M. Strath from the National Institute for Medical
Research, London, UK)49. On day 0, each mouse was injected i.p. with a dose of
10mg kg 1 of mAb NIMPR14, mixed with 60 ml of lip-clod (300 mg of clodronate).
On D2 and D4 and D6 each mouse received, i.p., 0.5ml of HRBC mixed with a
dose of 10mg kg 1 of mAb NIMP-R14 and 60 ml of lip-clod. On D8, each mouse
was injected with 0.5ml of HRBC infected with P. falciparum strains at a
parasitemia of 0.3%, mixed with a dose of 10mg kg 1 of mAb NIMP-R14 and
60ml of lip-clod. Following the P. falciparum infection, a dose of 10mg kg 1 of
mAb NIMP-R14 and 30ml of lip-clod was injected every 2–3 days. The haematocrit
and graft of HRBC in the peripheral blood of mice was followed up during the
assay in blood samples taken from the tail. After the P. falciparum infection, the
HRBC graft was carried out every 2–3 days except in those mice where their
haematocrit was up to 60% and the percentage of HRBC higher than 60%. Those
mice only received the immunosupressor treatment and the graft of HRBC was
carried out again once the haematocrit decreased to 50%.
PK studies. On the treatment day, all animals were weighed and the dosing
volume was calculated for each individual animal according to its actual body
weight. All animal were dosed once. Blood samples were taken at different time
points and plasma was collected after centrifugation (10,000g, 10min, 4 C).
Plasma samples were analysed by LC–MS/MS. During and after the application,
animals were observed for clinical signs and mortality. All relevant observations
were recorded. The PK studies in cynomolgus monkeys and beagle dogs were
performed by the Laboratory of Pharmacology and Toxicology (LPT), Hamburg,
and PK and toxicity studies in mice and rats were performed by the 4SC Discovery
GmbH, Munich. PK parameters were obtained by a non-compartment analysis,
using Kinetica 4.1 (Thermo Scientific).
In vitro generation of drug-resistant P. falciparum lines. To identify the mode of
action/mechanism of resistance of SC81458 and SC82388, a chemogenomic
approach was used, whereby resistant parasites were obtained by in vitro drug
pressure selection and subjected to whole-genome sequencing to identify the
genetic basis of resistance. Three independent selections of Dd2 parasites at an
initial population of 1010 infected red blood cells (performed in 150ml flasks, 2%
haematocrit) were subjected to SC81458 or SC83288 at a starting concentration of
50 nM. The drug pressure was gradually increased by increments of 50 nM up to
1 mM according to the parasite fitness. Drug resistance was confirmed by measuring
the IC50s, after two consecutive cycles in absence of the drug, using a SYBRGreen
growth inhibition assay as previously described45. After up to 200 days of drug
pressure, the drug-resistant lines were clones by limiting dilution for single-cell
isolation and genomic DNA was extracted using the DNeasy Blood&Tissue kit
(Qiagen, USA) and subjected to ultra-deep sequencing.
Whole-genome sequencing of isolates. Genomic DNA was extracted from eight
clones selected for reduced susceptibility to SC83288 and SC81458 resistant clones
and the Dd2 parent. Illumina libraries of 300–500 bp fragment length were
generated using a PCR-free protocol50 and sequenced using an Illumina
MiSeq obtaining 150 bp reads. The sequence data have been deposited in
the European Nucleotide Archive (ENA) under the accession code ERP005793
(https://www.ebi.ac.uk/ena/data/search?query=ERP005793). The accession
numbers of the reads are compiled in Supplementary Table 10.
Bioinformatics analysis. The analysis was performed as described13,14. In short,
to improve mapability the P. falciparum reference genome 3D7 was transformed
into the Dd2 parent clone by repeatedly mapping the reads and correcting the
differences using iCORN2 (ref. 51). Next, this new reference was annotated with
RATT52. Reads from all samples (Supplementary Table 10) were mapped against to
the new reference genomes using bowtie2 (ref. 53). Variants were called using two
methods: (i) the genome analysis toolkit (GATK) single-nucleotide polymorphism
calling pipeline54, using the settings for Plasmodium; and (ii) mpileup and varfilter
(varFilter -D 2000; Quality Z60) from the SAMtools package55. A bespoke PERL
script returns genes where just drug-resistant sample had single-nucleotide
polymorphisms. Last, large deletions, insertions and duplications were manually
detected using BAMview56.
Ca2þ live imaging. Trophozoite-stage P. falciparum HB3 parasites were
incubated with 10mM of Fluo-4-AM in RPMI 1640 medium (Life Technologies)
with Pluoronic F-127 (0.1% (v/v)) and 40 mM of probenecid for 40min at 37 C,
as previously described57. Dye-loaded parasites were washed two times before
settling onto poly-L-lysine-coated glass slides. Confocal laser scanning fluorescence
microscopy was performed using a Leica TCS SP5 (Leica Microsystems CMS
GmbH). Fluo-4-AM was excited at 488 nm (argon laser, 0.03%) and the emitted
fluorescence was collected from 505–520 nm. Single images were obtained using a
63 objective, with a fivefold software zoom, 1,024 1,024 pixels, every 2 s over a
time span of 120 s. The Ca2þ ATPase inhibitor CPA, the Naþ /Kþ ATPase
inhibitor oubain, SC81458 and SC83288 were added to a final concentration of
10 mM at 45 s. The calcium signal was further analysed using Fiji, and the mean
fluorescence signals were compared using one-way analysis of variance in
SigmaPlot 13 (Systat Software Inc.).
Gametocytocidal activity. Activity against early- and late-stage gametocytes was
determined in miniaturized 384-wells plate assays as previously described58,59.
Briefly, gametocytes from a recombinant line NF54Pfs16, expressing a green
fluorescent protein–luciferase reporter gene under the gametocyte-specific Pfs16
promoter were induced and purified as previously described60; gametocytes were
then treated either on day 1 (stage I gametocytes) or day 8 of gametocytogenesis
(stage IV gametocytes) with serially diluted SC81458 or SC83288 to achieve a final
top concentration of 40 mM (0.4% dimethylsulphoxide(DMSO)). After 72 h of
incubation, gametocyte inhibition was assessed by luminometry, after addition of
Steadylite plus luciferase detection kit (PerkinElmer) to the plate wells58,59.
Plasma protein binding of SC83288. The study was carried out by Novamass Ltd
(Oulu, Finland). The plasma protein binding of SC83288 was determined in
human rat, mouse and cynomolgus plasma, using a method based on rapid
equilibrium dialysis and LC/MS/MS analysis. Briefly, plasma from the different
species was incubated with a final concentration of SC83288 of 10 mM for 4 h
at 37 C in a rapid equilibrium dialysis device. Proteins were then precipitated
by acetonitrile addition containing a phenacetin internal standard. After
centrifugation (10,000g) the supernatants were analysed by LC/MS/MS to obtain
the protein unbound fraction of the analyte substance.
Inhibition of cytochrome P450 (CYP) enzymes. The study was conducted by
Novamass Ltd (Oulu, Finland) according to a previously established protocol61.
The inhibition potential of SC81458 and SC83288 towards drug-metabolizing
cytochrome P450 (CYP) was investigated using a cocktail incubation with 10
CYP-specific substrates and 13 probe reactions for nine major drug-metabolizing
CYP enzymes in incubation with a pool of human liver microsomes. Briefly, each
incubation mixture contained 0.5mg microsomal protein per ml, 0.1M phosphate
buffer (pH 7.4) and the 10 probe substrates, at the following concentrations:
melatonin (CYP1A2, 5 mM), coumarin (CYP2A6, 2 mM), bupropion (CYP2B6,
2 mM), amodiaquine (CYP2C8, 5 mM), tolbutamide (CYP2C9, 8 mM), omeprazole
(CYP2C19 and CYP3A4, 5 mM), dextromethorphan (CYP2D6, 1 mM),
chlorzoxazone (CYP2E1, 10 mM), midazolam (CYP3A4, 1 mM) and testosterone
(CYP3A4, 5 mM). SC81458 and SC83288 were dissolved into DMSO and added
into the incubation mixture to a final concentration of 10 mM. The reaction mixture
was preincubated for 2min at 37 C before the reaction was initiated by addition of
1mM NADPH. Each reaction was terminated after 20min by addition of ice-cold
acetonitrile containing a phenacetin internal standard. The samples were
subsequently cooled in an ice bath to precipitate the proteins centrifuged (10min,
16,200g). The supernatants were transferred to a Waters Max Recovery vial and
analysed by LC/MSMS.
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Screening for kinase inhibition of SC81458. The KINOMEscan was carried out
by Ambit (San Diego, USA) according to a previously established protocol62. The
experiment was based on a competition binding assay that quantitatively measures
the ability of a compound to compete with an immobilized, active-site directed
ligand. The assay is performed by combining three components: DNA-tagged
kinase; immobilized ligand; and a test compound. The ability of the test compound
to compete with the immobilized ligand is measured via quantitative PCR of the
DNA tag.
For most assays, kinase-tagged T7 phage strains were grown in parallel in
24-well blocks in an Escherichia coli host derived from the BL21 strain. E. coli were
grown to log-phase and infected with T7 phage from a frozen stock and incubated
with shaking at 32 C until lysis (90–150min). The lysates were centrifuged
(6,000g) and filtered (0.2 mm) to remove cell debris. The remaining kinases were
produced in HEK-293 cells (Sigma Aldrich, catalogue number: 85120602) and
subsequently tagged with DNA for quantitative PCR detection. Streptavidin-coated
magnetic beads were treated with biotinylated small molecule ligands for 30min at
RT to generate affinity resins for kinase assays. The liganded beads were blocked
with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% bovine
serum albumin, 0.05% Tween 20 and 1mM dithiothreitol) to remove unbound
ligand and to reduce non-specific phage binding. Binding reactions were assembled
by combining kinases, liganded affinity beads, and SC81458 in 1 binding buffer
(20% SeaBlock, 0.17 PBS, 0.05% Tween 20, 6mM dithiothreitol). SC81458 was
prepared as 40x stock in 100% DMSO and directly diluted into the assay to a final
concentration of 10 mM. All reactions were performed in polypropylene 384-well
plates in a final volume of 0.04ml. The assay plates were incubated at RT with
shaking for 1 h and the affinity beads were washed with wash buffer (1 PBS and
0.05% Tween 20). The beads were then resuspended in elution buffer (1 PBS,
0.05% Tween 20 and 0.5 mM non-biotinylated affinity ligand) and incubated at RT
with shaking for 30min. The kinase concentration in the eluates was measured by
quantitative PCR.
In vitro safety pharmacology profiling. The study was carried out by Cerep
(Celle l’Evescault, France). An in vitro pharmacological profiling panel was
designed to detect potential high-risk clinical adverse drug reactions. The panel
comprised of 54 targets. For assessment of activity against these tartgets, SC81458
and SC83288 were tested in an eight-point concentration–response covering up to
a test concentration of 10mM and an IC50 and Ki were determined using radi-
oligand binding assay.
The specific ligand binding to the receptors was defined as the difference
between the total binding and the non-specific binding determined in the presence
of an excess of unlabelled ligand. Results were expressed as a per cent of control
specific binding and as a per cent inhibition of control specific obtained in the
presence of the test compounds. Results showing an inhibition (or stimulation)
450% were considered to represent significant effects of the test compounds. 50%
was the cut-off value for further investigation (determination of IC50 or EC50 values
from concentration–response curves). The IC50 values were determined by
non-linear regression analysis of the competition curves generated with mean
replicate values using Hill equation curve fitting. The inhibition constants (Ki)
were calculated using the Cheng Prusoff equation.
Stability in cultured blood cell cultures. An enriched young trophozoite-stage
culture of P. falciparum Dd2 was obtain by magnetic purification and allowed to
recover for 1 h at 37 C in RPMI 1640 medium (Life Technologies) enriched with
1% hypoxanthine (C.C.Pro GmbH) and 10% Albumax (Life Technologies). The
experiment was performed in a total volume of 300ml, at a haematocrit of 50%,
in presence or absence of 2 mM of SC81458 or SC83288, for 6 h at 37 C under
shaking conditions. Each sample was subsequently treated with 1.2ml of ice-cold
acetonitrile, incubated on ice for 10min and centrifuged for 15min at 6,000g at
4 C. Supernatants were stored at  80 C until mass spectrometric measurement.
hERG profiling. A HEK 293 cell line (Sigma Aldrich, catalogue number: 85120602)
constitutively expressing the hERG channel in the membrane was used for the
assay. The cells were cultured in MEM with Earle’s salts and L-glutamine (10% FCS,
non-essential amino acids, 300 mgml 1 Geneticin (G418)) and kept at 37 C and
under 5% CO2. Cells were routinely split every 3–4 days at a 1:5–1:10 ratio.
The electrophysiological measurements were performed using the whole cell
patch-clamp method. Extracellular bath solution contained 137mM NaCl, 4mM
KCl, 1mM MgCl2, 1.8mM CaCl2, 10mM glucose, 10mM HEPES (pH 7.4 with
NaOH), the intracellular pipette solution 130mM KCl, 1mM MgCl2, 5mM
MgATP, 5mM EGTA and 10mM HEPES (pH 7.2 with KOH). To assess the effects
of SC81458 and SC83288 on the current through the hERG channel, a 1,500ms of
conditioning voltage pulse was applied every 20 s by the holding membrane
potential ( 80mV) is carried out to þ 40mV followed by a 500ms test pulse of
þ 40mV to  40mV. The amplitude of the current peak induced by the test pulse
was determined at equilibrium (I0) and after (Idrug) addition of the substance.
After the application of the substance, the cells were rinsed with extracellular bath
solution until a complete recovery of the current occurred; otherwise, the cells were
replaced with new ones.
Allometric scaling and prediction of human PK. An empirical four species
simple allometry according to the rule of exponents was used in predicting the
human total plasma clearance of SC83288 (ref. 30). The average body weights were
as following: mouse, 0.0287 kg; rat, 0.267 kg; monkey, 4.17 kg; and dog, 9.9 kg.
Values for the maximum lifespan potential were taken from Boxenbaum (1982)
and are: mouse, 2.66 years; rat, 4.48 years; monkey, 22.46 years; and dog, 22.20
years63. For man, a body weight of 70 kg and a maximum lifespan potential of
92.22 years were assumed. For a simple allometry with plasma protein binding
correction only mouse, rat and monkey were used since data on plasma protein
binding of SC83288 were only available for these three species. The preclinical
plasma concentration versus time profiles were analysed using a mPBPK model31.
A two tissue compartment version of the mPBPK model provided the best fits.
Total plasma clearance was parameterized as CL¼ aTBWb (TBW, total body
weight). Parameters a and b were derived from the mPBPK model. Volumes of
distribution were implemented as V1þV2þVp¼TBW, where Vp equals the
plasma volume of each species and V1 was parameterized as V1¼ cTBW. Fractions
of cardiac output fd1 and fd2 satisfied the condition fd1þ fd2r1. Values for
cardiac output were taken from Gabrielsson and Weiner64. A hematocrite of 0.42
was assumed for conversion to plasma flows. The parameters a, b, c, fd1, fd2 and
Kp (tissue/plasma partition coefficient) were estimated from a global fit of all data,
assuming a common fd1, fd2 and Kp for all species. Data below the lower limit of
quantification were excluded from the fit. A 1/y2pred weighting scheme was applied.
Assessment of model quality included visual inspection of the fitted curves,
residuals sum of squares, Akaike information criterion and coefficients of variation
of the estimated parameters. In the final model dog data were excluded since the
data could not be fitted together with the other three species, which was possibly
due to the different in vitro metabolite profile (Supplementary Fig. 5b). Parameters
for the other species could be derived with acceptable precision (Supplementary
Fig. 10b).
The mPBPK model was used to simulate the human PK and various dosing
schedules to obtain anticipated pharmacological active exposures, using the i.v.
route and different infusion protocols. The rate of infusion Cin is defined by the
equation Cin¼CssCL, where Css is the steady-state plasma concentration and CL
is the total plasma clearance rate. The simulations were based on point estimates of
the relevant parameter. Variability was not accounted for. Model fitting and
simulations were performed using Phoenix64/WinNonLin 6.4 on an Intel Core i5
processor.
Data availability. The authors declare that the data supporting the findings of this
study are available within the article and its supplementary information files,
or available from the authors upon request. The whole genome sequences of the
P. falciparum clone Dd2 and 8 P. falciparum clones resistant to SC83288 and
SC81458 have been deposited in the European Nucleotide Archive (ENA) under
the accession code ERP005793 (https://www.ebi.ac.uk/ena/data/search?query=
ERP005793).
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Erratum: SC83288 is a clinical development
candidate for the treatment of severe malaria
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Stefan Strobl, Cecilia P. Sanchez & Michael Lanzer
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This Article contains errors in Figs 1 and 8 that were introduced during the production process. The compound on the lower right side
of Fig. 1 is labelled incorrectly and should be labelled ‘SC83288’. The correct version of Fig. 1 appears below as Fig. 1. In Fig. 8c,
‘SC83458 selected’ should read ‘SC81458 selected’ and in Fig. 8d ‘SC81758’ should read ‘SC81458’. The correct version of Fig. 8 appears
below as Fig. 2.
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